Noboru Yamamoto1, Minal Barve2, Frans Opdam3, Hai-Yan Tu4, Yi-Long Wu4, David Berz5, Lukas Schroeter6, Maren Rohrbacher7, Behbood Sadrolhefazi8, John V Heymach9, Kiyotaka Yoh10
1Department of Experimental Therapeutics, National Cancer Center Hospital, 2Mary Crowley Cancer Research, 3Department of Clinical Pharmacology, The Netherlands Cancer Institute, 4Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Southern Medical University, 5Valkyrie Clinical Trials, Inc., 6Boehringer Ingelheim Pharma GmbH & Co. KG, 7Boehringer Ingelheim International GmbH, 8Boehringer Ingelheim Pharmaceuticals, Inc., 9Department of Thoracic / Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 10Department of Thoracic Oncology, National Cancer Center Hospital East
Japanese Journal of Lung Cancer 64(5): 410-410, 2024.